Bruker Corporation has finalized the purchase of the remaining 60 % of Swiss‑based TOFWERK AG, bringing its ownership of the company to 100 %. The transaction follows Bruker’s earlier minority stake acquisition in April 2022, when it paid CHF 18 million for an undisclosed share of TOFWERK. The deal value for the final 60 % was not disclosed.
TOFWERK, a developer of ultra‑fast time‑of‑flight (TOF) mass spectrometers, employs 130 people and reported 2025 revenues of roughly $40 million. Its product portfolio includes the Vocus TOF‑MS for air‑quality monitoring, microwave‑induced plasma systems for trace‑element analysis, and focused‑ion‑beam accessories for electron microscopes, all built on the company’s multi‑reflector TOF technology.
The acquisition is a key component of Bruker’s Project Accelerate strategy, which seeks to broaden the company’s mass‑spectrometry offerings into high‑margin, high‑volume applied markets such as semiconductor cleanroom monitoring, food and fragrance testing, and real‑time environmental analytics. By integrating TOFWERK’s rugged, high‑speed instruments, Bruker can deliver end‑to‑end solutions that extend beyond its traditional research and pharmaceutical segments.
Business analysts view the deal as a strategic win that adds a profitable, high‑growth business to Bruker’s portfolio. The combination is expected to generate immediate revenue synergies and cross‑selling opportunities across Bruker’s global customer base, strengthening its competitive moat in the applied analytics arena and positioning the company to capture growth in post‑genomic and industrial analytics markets.
Management comments underscore the strategic fit. Bruker CALID Group President Juergen Srega said the acquisition “perfectly complements our product offerings in small‑molecule mass spectrometry and expands our reach into high‑growth applied markets.” TOFWERK co‑founder Marc Gonin noted that joining Bruker “provides the scale needed to accelerate our impact in semiconductor and air‑quality monitoring.”
The transaction completes Bruker’s long‑standing M&A strategy of acquiring complementary technologies. The company’s prior minority stake in TOFWERK and the recent full acquisition signal a continued focus on expanding its applied mass‑spectrometry footprint and reinforcing its position against competitors such as Thermo Fisher Scientific and Agilent Technologies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.